Zymeworks Inc. (ZYME)
NASDAQ: ZYME · Real-Time Price · USD
29.63
+0.89 (3.10%)
Nov 6, 2026, 4:00 PM EST - Market closed
Zymeworks Employees
Zymeworks had 231 employees as of June 30, 2026. The number of employees decreased by 42 or 15.38% compared to the same quarter last year. That makes Zymeworks the 25,755th largest employer in the world and 3,279th in the United States.
Employees
231
Change (1Y)
-42
Growth (1Y)
-15.38%
Revenue / Employee
$160,723
Profits / Employee
-$649,316
Market Cap
2.10B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 231 | -42 | -15.38% | 231 | 0 |
| Mar 31, 2026 | 243 | -56 | -18.73% | 243 | 0 |
| Dec 31, 2025 | 264 | -22 | -7.69% | 264 | 0 |
| Sep 30, 2025 | 263 | -31 | -10.54% | 263 | 0 |
| Jun 30, 2025 | 273 | -17 | -5.86% | 273 | 0 |
| Mar 31, 2025 | 299 | 24 | 8.73% | 299 | 0 |
| Dec 31, 2024 | 286 | 8 | 2.88% | 280 | 6 |
| Sep 30, 2024 | 294 | 42 | 16.67% | 294 | 0 |
| Jun 30, 2024 | 290 | 53 | 22.36% | 290 | 0 |
| Mar 31, 2024 | 275 | -29 | -9.54% | 275 | 0 |
| Dec 31, 2023 | 278 | -16 | -5.44% | 272 | 6 |
| Sep 30, 2023 | 252 | -34 | -11.89% | 252 | 0 |
| Jun 30, 2023 | 237 | -47 | -16.55% | 237 | 0 |
| Mar 31, 2023 | 304 | -23 | -7.03% | 304 | 0 |
| Dec 31, 2022 | 294 | -164 | -35.81% | 291 | 3 |
| Sep 30, 2022 | 286 | -169 | -37.14% | 286 | 0 |
| Jun 30, 2022 | 284 | -141 | -33.18% | 284 | 0 |
| Mar 31, 2022 | 327 | -56 | -14.62% | 327 | 0 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,000 |
| Recursion Pharmaceuticals | 600 |
| Replimune Group | 465 |
| Vir Biotechnology | 367 |
| Vera Therapeutics | 362 |
| Biohaven | 274 |
| Immunome | 247 |
| Lakefront Biotherapeutics NV | 196 |
ZYME News
- 12 days ago - Zymeworks Transcript: Investor update - Transcripts
- 12 days ago - Zymeworks Press release: Investor update - Filings
- 12 days ago - Zymeworks Slides: Investor update - Filings
- 12 days ago - Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors - Business Wire
- 13 days ago - Zymeworks Proxy statement: Proxy filing - Filings
- 13 days ago - Zymeworks Proxy statement: Proxy filing - Filings
- 14 days ago - Zymeworks presents new clinical data from Phase 1 study of ZW191 - TheFly
- 14 days ago - Zymeworks presents new clinical data on Phase 1 study of ZW191 - TheFly